MLL3 is a <i>de novo</i> cause of endocrine therapy resistance

Abstract

Our data show that a decrease in functional MLL3 leads to endocrine therapy resistance. This highlights the importance of genotyping patient tumor samples for MLL3 mutation upon initial resection, prior to deciding upon treatment plans.